5NR Stock Chart & Stats
€27.88
-€0.12(-4.09%)
At close: 4:00 PM EST
€27.88
-€0.12(-4.09%)
Day’s Range― - ―
52-Week Range€12.16 - €47.86
Previous CloseN/A
Volume0.00
Average Volume (3M)39.00
Market Cap
€1.14B
Enterprise Value€1.56B
Total Cash (Recent Filing)€110.89M
Total Debt (Recent Filing)€106.61M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Apr 27, 2027EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding50,619,583
10 Day Avg. Volume0
30 Day Avg. Volume39
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€60.00Price Target Upside115.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€21.56M
Bulls Say, Bears Say
Bulls Say
Proprietary Oncology PlatformThe proprietary NBTXR3 platform addresses a clear therapeutic objective: increasing radiation’s local tumor effect while potentially engaging immune responses. If clinical development continues to validate these mechanisms, the platform could support differentiated combination treatments across oncology indications and create multiple partnering opportunities.
Strategic Janssen PartnershipThe Janssen relationship provides validation from a large pharmaceutical partner and creates a potential route to development and commercialization support. Collaboration, milestone, reimbursement, and eventual royalty economics could reduce the need for Nanobiotix to build a full commercial infrastructure independently.
2025 Revenue ReboundThe sharp 2025 revenue improvement indicates that the company’s collaboration-oriented model can produce meaningful inflows when development or partnership activity advances. The reported gross margin also suggests limited direct cost burden on recognized revenue, although repeatability still depends on future program and deal progress.
Bears Say
Persistent UnprofitabilityContinued net and operating losses show that Nanobiotix has not yet developed self-sustaining earnings power. This keeps results dependent on clinical progress, partnerships, and external financing, while ongoing losses can constrain strategic flexibility and make future profitability highly dependent on successful commercialization.
Ongoing Cash BurnPersistent operating and free-cash-flow outflows indicate that reported activity is not yet funding the business internally. The company therefore needs continued access to financing or collaboration proceeds to support research and operations, creating a durable risk if funding conditions or development timelines become less favorable.
Negative Equity And Rising DebtA negative equity base weakens financial resilience and makes leverage more difficult to manage, while rising debt adds obligations to an already loss-making business. This combination increases reliance on external funding and reduces the balance-sheet capacity available to absorb delays or additional development spending.
5NR FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €12.16 and its highest was €47.86 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.14B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Apr 27, 2027 which is in 201 days.
How were Nanobiotix SA’s earnings last quarter?
Nanobiotix SA released its earnings results on Sep 24, 2026. The company reported -€0.7 earnings per share for the quarter, missing the consensus estimate of -€0.25 by -€0.45.
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is 0.05.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Nanobiotix SA reported an EPS of -€0.7 in its last earnings report, missing expectations of -€0.25. Following the earnings report the stock price went down -1.131%.
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in DE:5NR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
5NR Stock 12 Month Forecast
Average Price Target
€60.00
▲(115.21% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―